… However, the risk of conservative suspension of CAR T-cell therapy to avoid the theoretical
… CAR T-cell therapy should commence once patients have clinically recovered from COVID-19…

… and given the constrained resources and uncertain therapeutic environment during the
COVID-19 pandemic, we suggest deferring these patients from CAR T cell therapy. …

… T cell therapy and coronavirus disease 2019 (COVID-19). Here, we refocus attention on
the biology of IL-6 and summarize the distinct pathological roles of IL-6 signaling in several …

… developing COVID-19 after treatment with CAR T cells. … COVID-19 after the first 6 months
post–CAR T-cell therapy, … a long period of time after cellular therapy. Currently, there are …

… shorter course of treatment that is implemented early, as is proposed for therapy of COVID-19–…
Therefore, we investigated infectious complications after tocilizumab use for CAR T-cell–…

… considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding …
COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy…

… response to COVID-19 vaccines in HSCT or CAR T-cell recipients. Our findings may inform
regular COVID-19 vaccination at appropriate intervals after HSCT or CAR T-cell therapy. …

… Since the COVID-19 situation varies substantially between and within countries, we … We
believe that patients having undergone HCT or are receiving CAR T-cell therapy can require …

… with immune effector cell-associated neurotoxicity … T-cell (CAR-T) therapy, a highly effective
treatment for refractory hematological malignancies. We investigated whether COVID-19-…

… COVID-19 after B-cell-targeted CAR-T-cell therapy have a very poor outcome. The COVID-19 …
affected by COVID-19 (Mortality Analyses—Johns Hopkins Coronavirus Resource Center (…